Ongoing mini-HTAs of medical technologies in Norway initiated in the second half of 2020

25

Dec 2020

In 2013, Norway established a framework for the introduction of innovations into the health care system through either a national or hospital-based health technology assessment. This framework is called the “New Method”.

In this framework, all innovations should undergo HTA before being funded. If the method concerns only one or two hospitals, the assessment shall be initiated by clinicians and ran at the hospital level. The final report is disseminated via a mini-HTA database. If the method is of national concern, it undergoes Single Technology Appraisal at the national level, followed by the funding decision by the group of payers (Decision Forum, Beslutningsforum).

In the second half of 2020, eight new mini-HTA projects of medical technologies were launched:

  • Intrathecal contrast-enhanced MRI in selecting adult hydrocephalus patients for shunt surgery (Oslo University Hospital)
  • Neuromuscular Electrical Stimulation for swallowing difficulties (Oslo University Hospital)
  • Composite tissue allotransplantation (Oslo University Hospital)
  • Histotyping (Artificial Intelligence) (Oslo University Hospital)
  • Intraoperative bronchoscopic assessment of tracheomalasia in vascular and oesophageal atresia repair (Oslo University Hospital)
  • Assessment of neuropathic face pain in invasive motor cortex stimulation (Oslo University Hospital)
  • Indirect calorimetry for measuring energy consumption in different patient groups (Oslo University Hospital)
  • Lipid apheresis treatment for indication lipoprotein (Vestfold Hospital Trust)

The full list can be seen here in Norwegian. 

After completion of the assessment, hospital management will make a decision about the funding of studied technology in a particular hospital.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First, EU issues of both newsletters are available for download free-of-charge.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

21

Mar 2022

The NHS Insights Prioritisation Programme (NIPP) is commissioned by the NHS Accelerated Access Collaborative (AAC) and the National Institute for Health Research (NIHR). It is designed to accelerate the evaluation and implementation of innovation that supports post-pandemic ways of working, builds service resilience, and delivers benefits to patients. Fourteen projects have been funded and have now commenced activity that will be ongoing until March 2023.

Read more

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more